Company news

Knight Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notice of Knight Therapeutics' Third Quarter 2026 Results Conference Call

October 29, 2026

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

October 6, 2026

Knight Therapeutics Announces Launch of TAVALISSE® in Brazil

October 6, 2026

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

September 29, 2026

Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)

September 29, 2026

Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies

September 25, 2026

Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada

September 15, 2026

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia

September 1, 2026

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

August 27, 2026

Knight Therapeutics Announces Launch of WYNZORA® in Canada

August 20, 2026

Knight Therapeutics Reports Second Quarter 2026 Results

August 6, 2026

Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call

July 30, 2026

Knight Therapeutics Announces Repayment of Revolving Credit Facility

June 17, 2026

Knight Announces Early Warning Filing Regarding Shares of Crescita

June 5, 2026

Knight to Present at the Jefferies 2026 Healthcare Conference in New York City

May 28, 2026

Knight Therapeutics Announces Launch of TAVALISSE® in Mexico

May 27, 2026

Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City

May 12, 2026

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil

May 8, 2026

Knight Therapeutics Reports First Quarter 2026 Results

May 7, 2026

Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call

April 30, 2026

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 15, 2026

Knight Therapeutics Inc. ranks on The Globe and Mail's second annual Canada's Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity

March 27, 2026

Knight Amends Normal Course Issuer Bid

March 23, 2026

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

March 19, 2026

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

March 17, 2026

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

March 17, 2026

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

March 17, 2026

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

March 17, 2026

Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call

March 12, 2026

Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

February 18, 2026

Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

February 18, 2026

Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

December 18, 2025

Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

December 18, 2025

Knight Therapeutics Reports Third Quarter 2025 Results

November 6, 2025

Knight Announces Closing of US$100 Million Revolving Credit Facility

October 31, 2025

Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

October 30, 2025

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

October 30, 2025

Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call

October 30, 2025

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

October 30, 2025

Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada

October 7, 2025

Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada

October 7, 2025

Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

October 7, 2025

Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

October 7, 2025

Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies

September 26, 2025

Knight Announces Normal Course Issuer Bid

August 20, 2025

Knight Therapeutics Reports Second Quarter 2025 Results

August 7, 2025

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

August 5, 2025

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

August 4, 2025

Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call

August 1, 2025

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

July 31, 2025

Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.